WO2014186728A3 - Methods for diagnosing and treating inflammatory bowel disease - Google Patents

Methods for diagnosing and treating inflammatory bowel disease Download PDF

Info

Publication number
WO2014186728A3
WO2014186728A3 PCT/US2014/038434 US2014038434W WO2014186728A3 WO 2014186728 A3 WO2014186728 A3 WO 2014186728A3 US 2014038434 W US2014038434 W US 2014038434W WO 2014186728 A3 WO2014186728 A3 WO 2014186728A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
inflammatory bowel
disease
diagnosing
bowel disease
Prior art date
Application number
PCT/US2014/038434
Other languages
French (fr)
Other versions
WO2014186728A2 (en
Inventor
Jason A. Hackney
Mary KEIR
Lilyan Yi Tian WRIGHT
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201480028634.6A priority Critical patent/CN105209643A/en
Priority to BR112015028338A priority patent/BR112015028338A2/en
Priority to KR1020157032445A priority patent/KR20160005044A/en
Priority to RU2015149032A priority patent/RU2015149032A/en
Priority to CA2910199A priority patent/CA2910199A1/en
Priority to JP2016514135A priority patent/JP2016521540A/en
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag filed Critical Genentech, Inc.
Priority to EP14797054.5A priority patent/EP2997162A4/en
Priority to MX2015015784A priority patent/MX2015015784A/en
Publication of WO2014186728A2 publication Critical patent/WO2014186728A2/en
Publication of WO2014186728A3 publication Critical patent/WO2014186728A3/en
Priority to US14/944,147 priority patent/US20160178644A1/en
Priority to HK16107516.2A priority patent/HK1219512A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Biomarkers for diagnosing inflammatory bowel disease, including Crohn's disease, including fibrotic or fibrostenotic Crohn's disease, and ulcerative colitis and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease, including fibrotic or fibrostenotic Crohn's disease, are provided.
PCT/US2014/038434 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease WO2014186728A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR112015028338A BR112015028338A2 (en) 2013-05-17 2014-05-16 methods of diagnosis or aid in the diagnosis and treatment of inflammatory bowel disease
KR1020157032445A KR20160005044A (en) 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease
RU2015149032A RU2015149032A (en) 2013-05-17 2014-05-16 METHODS FOR DIAGNOSIS AND TREATMENT OF INFLAMMATORY DISEASES OF THE GUT
CA2910199A CA2910199A1 (en) 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease
JP2016514135A JP2016521540A (en) 2013-05-17 2014-05-16 Diagnosis and treatment method for inflammatory bowel disease
CN201480028634.6A CN105209643A (en) 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease
EP14797054.5A EP2997162A4 (en) 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease
MX2015015784A MX2015015784A (en) 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease.
US14/944,147 US20160178644A1 (en) 2013-05-17 2015-11-17 Methods for diagnosing and treating inflammatory bowel disease
HK16107516.2A HK1219512A1 (en) 2013-05-17 2016-06-28 Methods for diagnosing and treating inflammatory bowel disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824661P 2013-05-17 2013-05-17
US61/824,661 2013-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/944,147 Continuation US20160178644A1 (en) 2013-05-17 2015-11-17 Methods for diagnosing and treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
WO2014186728A2 WO2014186728A2 (en) 2014-11-20
WO2014186728A3 true WO2014186728A3 (en) 2015-01-22

Family

ID=51899021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/038434 WO2014186728A2 (en) 2013-05-17 2014-05-16 Methods for diagnosing and treating inflammatory bowel disease

Country Status (11)

Country Link
US (1) US20160178644A1 (en)
EP (1) EP2997162A4 (en)
JP (1) JP2016521540A (en)
KR (1) KR20160005044A (en)
CN (1) CN105209643A (en)
BR (1) BR112015028338A2 (en)
CA (1) CA2910199A1 (en)
HK (1) HK1219512A1 (en)
MX (1) MX2015015784A (en)
RU (1) RU2015149032A (en)
WO (1) WO2014186728A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250599B1 (en) 2015-01-29 2021-04-14 Oxford University Innovation Limited Biomarker
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
SG10202106385XA (en) * 2016-12-29 2021-07-29 Univ Miami Method for modulating inflammasome activity and inflammation in the lung
WO2019018440A1 (en) * 2017-07-17 2019-01-24 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
GB201717301D0 (en) * 2017-10-20 2017-12-06 Nordic Bioscience As Type xvi collagen assay
JP2021513342A (en) * 2018-02-12 2021-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A method of predicting response to treatment by assessing the genetic heterogeneity of the tumor
WO2020113116A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
WO2020241778A1 (en) * 2019-05-29 2020-12-03 国立大学法人九州大学 Pharmaceutical composition for suppressing fibrosis
KR102577697B1 (en) * 2019-11-13 2023-09-14 주식회사 나이벡 Peptides for Inflammation Treatment and Wound healing
WO2021247548A1 (en) * 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Treatments for a sub-population of inflammatory bowel disease patients
WO2022140667A2 (en) * 2020-12-23 2022-06-30 Icahn School Of Medicine At Mount Sinai Method for treating crohn's disease
JPWO2023286694A1 (en) 2021-07-13 2023-01-19

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009339A2 (en) * 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Inflammatory bowel diseases
US20100093552A1 (en) * 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
US20110033486A1 (en) * 2009-07-20 2011-02-10 Abbas Alexander R Gene expression markers for crohn's disease
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
WO2012021773A1 (en) * 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009339A2 (en) * 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Inflammatory bowel diseases
US20100093552A1 (en) * 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
US20110033486A1 (en) * 2009-07-20 2011-02-10 Abbas Alexander R Gene expression markers for crohn's disease
WO2012021773A1 (en) * 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCKAIG ET AL.: "Differential expression of TGF-b isoforms by normal and inflammatory bowel disease intestinal myofibroblasts", AM J PHYSIOL CELL PHYSIOL, vol. 282, 2002, pages C172 - C182, XP003003258 *

Also Published As

Publication number Publication date
JP2016521540A (en) 2016-07-25
EP2997162A4 (en) 2017-02-01
MX2015015784A (en) 2016-03-11
EP2997162A2 (en) 2016-03-23
US20160178644A1 (en) 2016-06-23
CA2910199A1 (en) 2014-11-20
HK1219512A1 (en) 2017-04-07
KR20160005044A (en) 2016-01-13
WO2014186728A2 (en) 2014-11-20
CN105209643A (en) 2015-12-30
RU2015149032A (en) 2017-06-22
BR112015028338A2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
WO2014186728A3 (en) Methods for diagnosing and treating inflammatory bowel disease
EP2971127A4 (en) Methods for the diagnosis and treatment of inflammatory bowel disease
MX2022010809A (en) Methods for diagnosing and treating inflammatory bowel disease.
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
EP3131931A4 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
EP3065777A4 (en) Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
EP3430172A4 (en) Methods of diagnosing inflammatory bowel disease through rnaset2
HK1213522A1 (en) Methods for diagnosing and treating inflammatory bowel disease
EP3186397C0 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
WO2016106343A8 (en) Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
DK2900279T3 (en) GRPR ANTAGONISTS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF GRPR POSITIVE CANCER
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2013106273A3 (en) Peptides and methods of using same
EP3054977A4 (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
ZA201408059B (en) Compositions and methods for the treatment of inflammatory bowel disease
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
WO2015179835A3 (en) Mit biomarkers and methods using the same
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
EP3024482A4 (en) Methods for diagnosing and treating immune disease
HK1214752A1 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
HK1207420A1 (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
WO2017066796A3 (en) Modulators of telomere disease
WO2015187727A3 (en) Molecular mammography
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
EP3602041A4 (en) Methods for diagnosing and treating inflammatory bowel disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14797054

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2910199

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2014797054

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157032445

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/015784

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016514135

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015028338

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015149032

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015028338

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151111